Taking 4 of the top 5 spots in a ranking of HIV infection drug therapies in Q2 this year

Author：  

Publisher： Adis International

ISSN： 1173-5503

Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.330, 2001-01, pp. : 8-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Antiretroviral therapies in HIV-1 infection

By Morris-Jones S.   Moyle G.   Easterbrook P.J.  

Expert Opinion on Investigational Drugs, Vol. 6, Iss. 8, 1997-08 ,pp. : 1049-1062

Informa Healthcare

Access to resources Recommend Favorite

Drug interactions in the management of HIV infection

By Robertson Sarah M   Penzak Scott R   Pau Alice K  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 2, 2005-02 ,pp. : 233-253

Informa Healthcare

Access to resources Recommend Favorite

Cardiovascular disease and toxicities related to HIV infection and its therapies

By Zareba Karolina M   Miller Tracie L   Lipshultz Steven E  

Expert Opinion on Drug Safety, Vol. 4, Iss. 6, 2005-11 ,pp. : 1017-1025

Informa Healthcare

Access to resources Recommend Favorite

Management of HIV infection complicated by drug interactions

By  

Inpharma, Vol. 1, Iss. 1282, 2001-01 ,pp. : 3-3

Adis International

Access to resources Recommend Favorite

Lersivirine – a new drug for HIV infection therapy

By Platten Martin   Fätkenheuer Gerd  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 12, 2013-12 ,pp. : 1687-1694

Informa Healthcare

Access to resources Recommend Favorite